Blosozumab

Blosozumab binds SOST, a negative regulator of osteoblast activity.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozaumab has been studied with regard to the treatment of osteoporosis in both men and postmenopausal women.

Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect. Blosozumab was developed by Eli Lilly and Company.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1325203232 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.